Search Results - "ALFONSO, Pilar"

First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study by Lenz, Heinz-Josef, Van Cutsem, Eric, Luisa Limon, Maria, Wong, Ka Yeung Mark, Hendlisz, Alain, Aglietta, Massimo, García-Alfonso, Pilar, Neyns, Bart, Luppi, Gabriele, Cardin, Dana B, Dragovich, Tomislav, Shah, Usman, Abdullaev, Sandzhar, Gricar, Joseph, Ledeine, Jean-Marie, Overman, Michael James, Lonardi, Sara

“…Nivolumab received US Food and Drug Administration approval as a single agent or in combination with ipilimumab in patients with microsatellite…”
Get full text

Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study by Dasari, Arvind, Lonardi, Sara, Garcia-Carbonero, Rocio, Elez, Elena, Yoshino, Takayuki, Sobrero, Alberto, Yao, James, García-Alfonso, Pilar, Kocsis, Judit, Cubillo Gracian, Antonio, Sartore-Bianchi, Andrea, Satoh, Taroh, Randrian, Violaine, Tomasek, Jiri, Chong, Geoff, Paulson, Andrew Scott, Masuishi, Toshiki, Jones, Jeremy, Csőszi, Tibor, Cremolini, Chiara, Ghiringhelli, Francois, Shergill, Ardaman, Hochster, Howard S, Krauss, John, Bassam, Ali, Ducreux, Michel, Elme, Anneli, Faugeras, Laurence, Kasper, Stefan, Van Cutsem, Eric, Arnold, Dirk, Nanda, Shivani, Yang, Zhao, Schelman, William R, Kania, Marek, Tabernero, Josep, Eng, Cathy

“…There is a paucity of effective systemic therapy options for patients with advanced, chemotherapy-refractory colorectal cancer. We aimed to evaluate the…”
Get full text

Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study by Tabernero, Josep, Dr, Yoshino, Takayuki, MD, Cohn, Allen Lee, MD, Obermannova, Radka, MD, Bodoky, Gyorgy, Prof, Garcia-Carbonero, Rocio, MD, Ciuleanu, Tudor-Eliade, Prof, Portnoy, David C, MD, Van Cutsem, Eric, Prof, Grothey, Axel, MD, Prausová, Jana, MD, Garcia-Alfonso, Pilar, PhD, Yamazaki, Kentaro, MD, Clingan, Philip R, Prof, Lonardi, Sara, MD, Kim, Tae Won, Prof, Simms, Lorinda, MS, Chang, Shao-Chun, PhD, Nasroulah, Federico, MD

“…Summary Background Angiogenesis is an important therapeutic target in colorectal carcinoma. Ramucirumab is a human IgG-1 monoclonal antibody that targets the…”
Get full text

Systematic review of randomised clinical trials and observational studies for patients with RAS wild-type or BRAFV600E-mutant metastatic and/or unresectable colorectal cancer by García-Alfonso, Pilar, Lièvre, Astrid, Loupakis, Fotios, Tadmouri, Abir, Khan, Sadya, Barcena, Leticia, Stintzing, Sebastian

“…Approximately 8–10% of metastatic colorectal cancer (mCRC) tumours harbour BRAFV600E mutations. Eleven randomised controlled trials (RCTs) and 24 non-RCTs were…”
Get full text

Delphi consensus for the third-line treatment of metastatic colorectal cancer by García-Alfonso, Pilar, Vera, Ruth, Aranda, Enrique, Élez, Elena, Rivera, Fernando

“…Purpose The optimal drug regimen and sequence are still unknown for patients with metastatic colorectal cancer (mCRC) who are candidates for third-line (3L) or…”
Get full text

Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study by Kawazoe, Akihito, Xu, Rui-Hua, García-Alfonso, Pilar, Passhak, Maria, Teng, Hao-Wei, Shergill, Ardaman, Gumus, Mahmut, Qvortrup, Camilla, Stintzing, Sebastian, Towns, Kathryn, Kim, Tae Won, Shiu, Kai Keen, Cundom, Juan, Ananda, Sumitra, Lebedinets, Andrey, Fu, Rong, Jain, Rishi, Adelberg, David, Heinemann, Volker, Yoshino, Takayuki, Elez, Elena

“…Treatment options are limited for patients with previously treated metastatic colorectal cancer (mCRC). In the LEAP-017 study, we evaluate whether lenvatinib…”
Get full text

The McCAVE Trial: Vanucizumab plus mFOLFOX‐6 Versus Bevacizumab plus mFOLFOX‐6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC) by Bendell, Johanna C., Sauri, Tamara, Gracián, Antonio Cubillo, Alvarez, Rafael, López‐López, Carlos, García‐Alfonso, Pilar, Hussein, Maen, Miron, Maria‐Luisa Limon, Cervantes, Andrés, Montagut, Clara, Vivas, Cristina Santos, Bessudo, Alberto, Plezia, Patricia, Moons, Veerle, Andel, Johannes, Bennouna, Jaafar, Westhuizen, Andre, Samuel, Leslie, Rossomanno, Simona, Boetsch, Christophe, Lahr, Angelika, Franjkovic, Izolda, Heil, Florian, Lechner, Katharina, Krieter, Oliver, Hurwitz, Herbert

“…Background Bevacizumab, a VEGF‐A inhibitor, in combination with chemotherapy, has proven to increase progression‐free survival (PFS) and overall survival in…”
Get full text

Olaparib with or without bevacizumab versus bevacizumab plus a fluoropyrimidine as maintenance therapy in advanced colorectal cancer: The randomized phase 3 LYNK-003 study by Takashima, Atsuo, García-Alfonso, Pilar, Manneh, Raimundo, Beşen, Ali Ayberk, Hong, Yong Sang, Cuyle, Pieter-Jan, Yanez, Patricio, Burge, Matthew, Yoshino, Takayuki, Kim, Tae Won, Cui, Karen, Li, Chenxiang, Jain, Rishi, Adelberg, David, Taieb, Julien

“…The randomized, open-label, phase III LYNK-003 study assessed the efficacy of first-line maintenance olaparib, alone or in combination with bevacizumab, versus…”
Get full text

Perioperative trastuzumab, capecitabine and oxaliplatin in patients with HER2-positive resectable gastric or gastro-oesophageal junction adenocarcinoma: NEOHX phase II trial by Rivera, Fernando, Izquierdo-Manuel, Marta, García-Alfonso, Pilar, Martínez de Castro, Eva, Gallego, Javier, Limón, María Luisa, Alsina, María, López, Luis, Galán, Maica, Falcó, Esther, Manzano, José Luis, González, Encarna, Muñoz-Unceta, Nerea, López, Carlos, Aranda, Enrique, Fernández, Eva, Jorge, Mónica, Jiménez-Fonseca, Paula

“…Perioperative chemotherapy improves overall survival (OS) and disease-free survival (DFS) compared with surgery alone in patients with resectable gastric…”
Get full text

Liquid Biopsy Detects Early Molecular Response and Predicts Benefit to First-Line Chemotherapy plus Cetuximab in Metastatic Colorectal Cancer: PLATFORM-B Study by Vidal, Joana, Fernández-Rodríguez, Maria Concepción, Casadevall, David, García-Alfonso, Pilar, Páez, David, Guix, Marta, Alonso, Vicente, Cano, Maria Teresa, Santos, Cristina, Durán, Gema, Elez, Elena, Manzano, José Luís, Garcia-Carbonero, Rocío, Ferreiro, Reyes, Losa, Ferran, Pineda, Estela, Sastre, Javier, Rivera, Fernando, Bellosillo, Beatriz, Tabernero, Josep, Aranda, Enrique, Salazar, Ramon, Montagut, Clara

“…Chemotherapy plus anti-EGFR is standard first-line therapy in RAS wild-type (wt) metastatic colorectal cancer (mCRC), but biomarkers of early response are…”
Get full text

Single‐Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial) by García‐Alfonso, Pilar, Benavides, Manuel, Falcó, Esther, Muñoz, Andrés, Gómez, Auxiliadora, Sastre, Javier, Rivera, Fernando, Montagut, Clara, Salgado, Mercedes, López‐Ladrón, Amelia, López, Rafael, Ruiz de Mena, Inmaculada, Durán, Gema, Aranda, Enrique

“…Lessons Learned RAS‐ or BRAF‐mutated metastatic colorectal cancers (mCRCs) progressing after first‐line treatment have a poor prognosis. European and U.S…”
Get full text

Randomized, double‐blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancer by Fogelman, David, Cubillo, Antonio, García‐Alfonso, Pilar, Mirón, María Luisa Limón, Nemunaitis, John, Flora, Daniel, Borg, Christophe, Mineur, Laurent, Vieitez, Jose M., Cohn, Allen, Saylors, Gene, Assad, Albert, Switzky, Julie, Zhou, Li, Bendell, Johanna

“…Background The Janus kinase/signal transducer and activator of transcription (JAK‐STAT) signaling pathway plays a key role in the systemic inflammatory…”
Get full text

Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-Line RAS Wild-Type Metastatic Colorectal Cancer by Hill, Andrew G, Findlay, Michael P, Burge, Matthew E, Jackson, Christopher, Alfonso, Pilar Garcia, Samuel, Leslie, Ganju, Vinod, Karthaus, Meinolf, Amatu, Alessio, Jeffery, Mark, Bartolomeo, Maria Di, Bridgewater, John, Coveler, Andrew L, Hidalgo, Manuel, Kapp, Amy V, Sufan, Roxana I, McCall, Bruce B, Hanley, William D, Penuel, Elicia M, Pirzkall, Andrea, Tabernero, Josep

“…Duligotuzumab is a dual-action antibody directed against EGFR and HER3. Metastatic colorectal cancer (mCRC) patients with ex2 wild-type received duligotuzumab…”
Get full text

Biomarkers Associated with Regorafenib First-Line Treatment Benefits in Metastatic Colorectal Cancer Patients: REFRAME Molecular Study by Conde, Elisa, Earl, Julie, Crespo-Toro, Lorena, Blanco-Agudo, Carolina, Ramos-Muñoz, Edurne, Rodríguez-Serrano, E Macarena, Martínez Ávila, Jose Carlos, Salinas-Muñoz, Laura, Serrano-Huertas, Silvia, Ferreiro, Reyes, Rodriguez-Garrote, Mercedes, Sainz, Jr, Bruno, Massuti, Bartomeu, Alfonso, Pilar García, Benavides, Manuel, Aranda, Enrique, García-Bermejo, María Laura, Carrato, Alfredo

“…First-line treatment with regorafenib in frail metastatic colorectal cancer (mCRC) patients has shown some benefit. To accurately identify such patients before…”
Get full text

Oral drugs in the treatment of metastatic colorectal cancer by García-Alfonso, Pilar, Muñoz Martín, Andrés Jesús, Ortega Morán, Laura, Soto Alsar, Javier, Torres Pérez-Solero, Gabriela, Blanco Codesido, Montserrat, Calvo Ferrandiz, Pilar Aitana, Grasso Cicala, Silvina

“…Colorectal cancer (CRC) is one of the most common forms of cancer, with an estimated 1.36 million new cases and almost 700,000 deaths annually. Approximately…”
Get full text

Recommendations for SIR-Spheres Y-90 resin microspheres in chemotherapy-refractory/intolerant colorectal liver metastases by Aranda, Enrique, Aparicio, Jorge, Bilbao, José Ignacio, Alfonso, Pilar García, Maurel, Joan, Rodríguez, Javier, Sangro, Bruno, Vieitez, José María, Feliu, Jaime

“…A Spanish expert panel reviewed current evidence for the use of SIR-Spheres Y-90 resin microspheres in patients with chemotherapy refractory/intolerant…”
Get full text

Identification of new SNPs associated with severe toxicity to capecitabine by Pellicer, Marta, García-González, Xandra, García, María I., Robles, Luis, Grávalos, Cristina, García-Alfonso, Pilar, Pachón, Vanessa, Longo, Federico, Martínez, Virginia, Blanco, Carolina, Iglesias, Irene, Sanjurjo, María, López-Fernández, Luis A.

“…[Display omitted] Predicting individual risk of chemotherapy-induced severe adverse reaction is a critical issue when selecting the best treatment for cancer…”
Get full text

Differences in the Therapeutic Approach to Colorectal Cancer in Young and Elderly Patients by Serra‐Rexach, José A., Jimenez, Ana B., García‐Alhambra, María A., Pla, Rosa, Vidán, Maite, Rodríguez, Paz, Ortiz, Javier, García‐Alfonso, Pilar, Martín, Miguel

“…Learning Objectives After completing this course, the reader will be able to: Use patient age as only one consideration, along with tumor status and…”
Get full text

Recommendations for the optimal management of peritoneal metastases in patients with colorectal cancer: a TTD and GECOP-SEOQ expert consensus statement by Grávalos, Cristina, Pereira, Fernando, Vera, Ruth, Arjona-Sánchez, Alvaro, Losa, Ferran, Ramos, Isabel, García-Alfonso, Pilar, Gonzalez-Bayón, Luis, Cascales-Campos, Pedro Antonio, Aranda, Enrique

“…Peritoneal metastases (PM) occur when cancer cells spread inside the abdominal cavity and entail an advanced stage of colorectal cancer (CRC). Prognosis, which…”
Get full text

SEOM-GEMCAD-TTD clinical guidelines for the systemic treatment of metastatic colorectal cancer (2022) by Fernández Montes, Ana, Alonso, Vicente, Aranda, Enrique, Élez, Elena, García Alfonso, Pilar, Grávalos, Cristina, Maurel, Joan, Vera, Ruth, Vidal, Rosario, Aparicio, Jorge

“…Colorectal cancer (CRC) is the second leading cause of cancer deaths in Spain. Metastatic disease is present in 15–30% of patients at diagnosis and up to…”
Get full text